Letter to the Editor: Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer

Abstract

Get full access to this article

View all access options for this article.

References

, Grewal

, Leboeuf

, et al. 2013. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med, 368:623–632.

Buffet

, Wassermann

, Hecht

, et al. 2020. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr Relat Cancer, 27:R113–R132.

Groussin

, Clerc

, Huillard

. 2020. Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer. N Engl J Med, 383:1686–1687.

Wirth

, Sherman

, Robinson

, et al. 2020. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med, 383:825–835.

Subbiah

, Shen

, Terzyan

, et al. 2021. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol, 32:261–268.